top of page
RyboDyn website homepage main image.jpg


Targeting the dark proteome

RyboDyn is on the cutting edge of exploiting a novel proteome for therapeutic targeting. We are hard at work finding and prioritizing ideal targets for the next generation of immunotherapies: disease-specific proteins displayed on cell surfaces.


Over half of all immunotherapies fail in clinical trials because they attack healthy cells. Safety issues are by far the biggest collective "pain point" hindering progress in this field. At RyboDyn, we are solving this problem through exquisite selectivity. Our targets are exclusive to cancer cells (not found in any healthy human database), are not reported in current literature, and have been recently discovered and validated by premier scientists.


RyboDyn is using these cancer-specific targets to create a new, disruptive class of antibodies designed to seek cancer cells with ultra-high specificity.

Rybodyn Photo Background.webp

We are making a new generation of therapeutic antibodies

Background Squares.webp
Our Services
Background Squares.webp

Why RyboDyn?

Scientists are known for their objectivity, persistence, and analytic thinking. But the best scientists have something else in common: they think like artists. And for those who create life-changing medicines and methods to produce them, their process is as much an art form as a science.

Credible Solutions

Workflows are held to the highest standard to make a real difference.


We pioneer a new class of methods and treatments for significant and far-reaching improvements. 

Life Changing

Bring the future to today through clinical testing and breakthrough science.

What drives the team

“My life's work has uncovered methods that change the way we look at terminal illnesses.”

Corey M. Dambacher
Chief Scientist, CEO and Founder

Discover New Opportunities

All great discoveries start in a knowledgeable mind but often the most impactful ones take many hands to lift. Connect with our team to find out how you can play a vital role in the future of research medicine.

bottom of page